$1.32
+0.02 (+1.54%)
Open$1.29
Previous Close$1.30
Day High$1.34
Day Low$1.27
52W High$5.30
52W Low$1.25
Volume—
Avg Volume36.8K
Market Cap3.36M
P/E Ratio—
EPS$1.07
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+2,068.9% upside
Current
$1.32
$1.32
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 250.8K | 547.7K | 3.56M |
| Net Income | -4,332,684 | -8,515,867 | 452.9K |
| Profit Margin | -1,727.8% | -1,641.4% | 12.7% |
| EBITDA | -4,092,333 | -8,490,317 | 509.0K |
| Free Cash Flow | — | — | 445.4K |
| Rev Growth | -54.2% | -54.2% | +0.2% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |